| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/07/1996 | CA2198479A1 Method for enhancing immunogenicity, product obtained and pharmaceutical composition |
| 03/07/1996 | CA2198474A1 Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle |
| 03/07/1996 | CA2198473A1 Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound |
| 03/07/1996 | CA2198472A1 Genetic therapy of vascular diseases with a cell-specific active substance which is dependent on the cell cycle |
| 03/07/1996 | CA2198362A1 Topical anti-inflammatory composition and method |
| 03/07/1996 | CA2198080A1 Cell cycle regulated repressor and dna element |
| 03/07/1996 | CA2196063A1 Cosolvent parenteral formulation of tirilazad |
| 03/07/1996 | CA2195874A1 Aerosol drug formulations containing polyglycolyzed glycerides |
| 03/06/1996 | EP0699766A1 Therapeutic antibody based fusion proteins with platelet factor-4 |
| 03/06/1996 | EP0699439A2 Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors |
| 03/06/1996 | EP0699436A1 Controlled release formulation |
| 03/06/1996 | EP0699433A2 Cosmetic or pharmaceutical composition containing chitosan derivatives |
| 03/06/1996 | EP0699432A1 Cosmetic and/or dermatologic composition containing thermal or mineral water and an active agent against acnee or ageing |
| 03/06/1996 | EP0699079A1 Bioactive and/or targeted dendrimer conjugates |
| 03/06/1996 | EP0670714A4 Retinoic acid-containing compositions. |
| 03/06/1996 | EP0630231B1 Liposomes with excess negative charge |
| 03/06/1996 | EP0395653B1 Synovial phospholipases |
| 03/06/1996 | CN1118168A Structured copolymers used as absorbents, gels and carriers of metal ions |
| 03/06/1996 | CN1118160A Polyamine derivatives as radioprotective agents |
| 03/06/1996 | CN1118143A Excipient stabilization of polypeptides treated with organic solvents |
| 03/06/1996 | CN1118136A Methods for in vivo delivery of biologics and compositions useful therefor |
| 03/06/1996 | CN1117875A Composition consisting of a dendrimer and an active substance occluded in the dendrimer, a process for the preparation of such a composition and a process for releasing the active substance |
| 03/06/1996 | CN1117874A Nasally administrable compositions |
| 03/06/1996 | CN1117851A Yinhuang Lozenge and its preparation method |
| 03/05/1996 | US5496934 Nucleic acids encoding a cellulose binding domain |
| 03/05/1996 | US5496827 Compositions for the transdermal delivery of nutrients |
| 03/05/1996 | US5496819 Drug delivery |
| 03/05/1996 | US5496809 Of water, 8-n-(diethylaminoethyl)rebeccamycin and a pharmaceutically acceptable acid |
| 03/05/1996 | US5496801 Storage stability, mannitol, citric acid buffer |
| 03/05/1996 | US5496567 Vitamin supplements |
| 03/05/1996 | US5496565 Microspherules |
| 03/05/1996 | US5496564 Suspendible composition and process for preparing the same |
| 03/05/1996 | US5496563 Dry gel composition |
| 03/05/1996 | US5496561 Time-release agents for drugs from membrane layers of polymers |
| 03/05/1996 | US5496558 Solid form xerostomia product |
| 03/05/1996 | US5496557 Wall is composed of two degradable polymers, one permeable to active substance, the other poorly permeable; polymers are poly/ortho/esters, poly-alpha-amino acids, polydepsipeptides, polyanhydrides, polyphosphazenes, copolymers, stereo complexes |
| 03/05/1996 | US5496549 Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis |
| 03/05/1996 | US5496545 Phosphate-binding polymers for oral administration |
| 03/05/1996 | US5496535 Gas generating agent, improved palatability, magnetic resonance imaging |
| 03/05/1996 | US5496471 Apparatus for removing components from solutions |
| 03/05/1996 | CA2010022C Anesthetic oral compositions |
| 02/29/1996 | WO1996006116A1 Immunoconjugates comprising tyrosine kinase inhibitors |
| 02/29/1996 | WO1996006114A1 Cytadherence peptides for use in modifying mutual adhesion among eukaryotic cells |
| 02/29/1996 | WO1996005865A1 Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer |
| 02/29/1996 | WO1996005864A1 Solid pharmaceutical form for the administration of a liposoluble liquid active substance |
| 02/29/1996 | WO1996005863A1 Compounds, pharmaceutical composition and diagnostic device comprising same and their use |
| 02/29/1996 | WO1996005857A1 Device for delivery of substances and methods of use thereof |
| 02/29/1996 | WO1996005843A1 Pharmaceutical compositions comprising co-dried sucralfate gel and polyalcohol |
| 02/29/1996 | WO1996005842A1 Intravenous alendronate formulations |
| 02/29/1996 | WO1996005834A1 Improved pharmaceutical formulations containing ibuprofen and codeine |
| 02/29/1996 | WO1996005815A1 Oestradiol-containing transdermal therapeutic system comprising hydrophylic additives |
| 02/29/1996 | WO1996005814A1 Oestradiol transdermal therapeutic system comprising hygroscopic additives |
| 02/29/1996 | WO1996005812A1 Hydrophilic controlled release device |
| 02/29/1996 | WO1996005810A1 Drug delivery composition containing chitosan or derivative thereof having a defined z. potential |
| 02/29/1996 | WO1996005809A1 Improved method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
| 02/29/1996 | WO1996001128A3 Low-dose steroid tablets containing gallic acid esters as antioxidant agent, process for the manufacture of said tablets, and uses of said tablets |
| 02/29/1996 | WO1995032735A3 Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease |
| 02/29/1996 | DE4430601A1 Zelladhäsions-Peptide zur Modifikation des Haftungsverhaltens eukaryontischer Zellen untereinander Cell adhesion peptides to modify the adhesion behavior of eukaryotic cells between each other |
| 02/29/1996 | DE4429747A1 Cosmetic ointment and cream bases |
| 02/29/1996 | CA2198207A1 Cell adhesion peptides for use in modifying mutual adhesion among eukaryotic cells |
| 02/29/1996 | CA2197577A1 Immunoconjugates comprising tyrosine kinase inhibitors |
| 02/29/1996 | CA2188948A1 Device for delivery of substances and methods of use thereof |
| 02/28/1996 | EP0698393A1 Solubilizing agent and external preparation containing the same |
| 02/28/1996 | EP0698389A1 Controlled release matrix for pharmaceuticals |
| 02/28/1996 | EP0698113A1 Production of toxin binding biopolymers, use thereof |
| 02/28/1996 | EP0698109A1 Gene transfer into pancreatic and biliary epithelial cells |
| 02/28/1996 | EP0698040A1 Lhrh antagonists |
| 02/28/1996 | EP0698018A1 Inclusion complexes of taxol or taxotere or taxus extract formed with cyclodextrins, its preparation and use |
| 02/28/1996 | EP0697891A1 Polyoxime compounds and their preparation |
| 02/28/1996 | EP0697890A1 More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent |
| 02/28/1996 | EP0697889A1 COMBINED TREATMENT OF IRON DEPLETION AND IgG ANTIBODY |
| 02/28/1996 | EP0697887A1 Stable liquid compositions of gamma interferon |
| 02/28/1996 | EP0697881A1 New cyclosporine-containing pharmaceutical compositions for oral administration |
| 02/28/1996 | EP0697874A1 Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor |
| 02/28/1996 | EP0697867A1 Compositions in the form of solid solutions |
| 02/28/1996 | EP0697866A1 High dose formulations |
| 02/28/1996 | EP0697860A1 Transdermal therapeutic system containing estradiol |
| 02/28/1996 | EP0697859A1 Stable, ingestable and absorbable nadh and nadph therapeutic compositions |
| 02/28/1996 | EP0697858A1 Nasal drug delivery composition containing nicotine |
| 02/28/1996 | EP0697821A1 Cholesterol lowering drink mix compositions |
| 02/28/1996 | EP0661966A4 Ulcer prevention and treatment composition and method. |
| 02/28/1996 | EP0630644A4 Anti-microbial and interferon-inducing pharmaceutical compound. |
| 02/28/1996 | EP0588897B1 Non-chlorofluorocarbon aerosol formulations |
| 02/28/1996 | EP0572502A4 Polyamino acid dispersants |
| 02/28/1996 | EP0547126B1 Biodegradable polymers containing diester units |
| 02/28/1996 | EP0533836B1 Reversible gelation compositions and methods of use |
| 02/28/1996 | CN1117383A Cefixime composition |
| 02/27/1996 | US5494938 Comprisinga water insoluable oil, alkyl glucosides and fatty acid glycerides; storage stability, homogeneity |
| 02/27/1996 | US5494936 Delivery formulation for probucol |
| 02/27/1996 | US5494901 Includes carbonic anhydrase inhibitor |
| 02/27/1996 | US5494683 Surface modified anticancer nanoparticles |
| 02/27/1996 | US5494682 Encapsulated biomass in crosslinked polymer material |
| 02/27/1996 | US5494681 Molten blend of active material, spatially oriented matrix comprising wax core material, hydrophobic polymer |
| 02/27/1996 | US5494680 Transdermal delivery device |
| 02/27/1996 | US5494679 Molecules for iontophoretic delivery |
| 02/27/1996 | US5494665 Metal chloride, lysozyme chloride, isotonic agent, nonionic thickening agent and preservative |
| 02/27/1996 | CA2170505A1 Compositions and methods for the administration of .delta.-aminolevulinic acid and pharmaceutical equivalents thereof |
| 02/27/1996 | CA2030204C Pharmaceutical compositions of tebufelone |
| 02/24/1996 | CA2156768A1 Pharmaceutical formulations, their preparation and use |
| 02/22/1996 | WO1996005320A1 Adenovirus comprising a gene coding for glutathion peroxidase |